Analysts Reports
-
Immuron Limited – September Quarter 2024 Update – Litchfield Hills Research (October 2024)
-
Immuron Limited – Litchfield Hills Research - Initiation Report (September 2024)
-
Immuron Limited – Mecca Partners (September 2024)
-
Immuron Limited – Bioshares update (September 2024)
-
Immuron Limited FY24 Results Note – Henslow Research (September 2024)
-
Immuron: Continually breaking sales records – Pitt Street Research (July 2024)
-
Immuron Limited 4Q24 Sales Update – Henslow Research (July 2024)
-
Immuron Limited – Bioshares update (May 2024)
-
Immuron Limited 3Q24 Sales Update – Henslow Research (April 2024)
-
Immuron: Soon to enter the ‘Phase 3 club’ – Pitt Street Research (March 2024)
-
Immuron Limited 1H24 Results Note - Henslow Research (March 2024)
-
Immuron Limited: Progressing fast with clinical trials (February 2024)
-
Immuron Limited 1H24 Sales Update - Henslow Research (January 2024)
-
Immuron Limited: Immunity for the gut (November 2023)
-
Immuron Limited FY23 Results - Henslow Research (September 2023)
-
Immuron Limited Bioshares Report – (May 2023)
-
Immuron Limited 1H 2023 Results – Henslow Research (Mar 2023)
-
Immuron Equity Report (Oct 2019)
-
Immuron takes aim at the rapid growth of autoimmune diseases
-
Immuron surges 28pc after study shows tablets fight Bali Belly in US soldiers (Jan 2018)
-
Van Leeuwenhoeck Institute Updated Report (Nov 2017)
-
Emerging Biologics in Fatty-Liver and Infectious Disease Management (Sep 2017)
-
BioShares Report - Edition 687 (Mar 2017)
-
Van Leeuwenhoeck Institute Report - Substantial Re-rating in NASH (Feb 2017)
-
Van Leeuwenhoeck Institute Independent Research Note (Jan 2017)
-
SeeThru Equity Analyst Report (Feb 2016)
-
Red Chip C-Difficile Analyst Report (Jan 2016)
-
Red Chip Analyst Report (Aug 2015)
